Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis

Table 2 Clinical features and outcomes of PSC-IBD patients

Clinical features	n = 75
Age at PSC diagnosis (yr) (SD)	35.8 (15.6)
Age at IBD diagnosis (yr) (SD)	27.8 (14)
Disease topography	Intrahepatic	42%
	Intra- and extrahepatic	55.10%
	Extrahepatic	2.90%
Morphologic examinations	ERCP	50.70%
	MRCP	77.30%
	Endoscopic ultrasound	17.30%
	Liver biopsy	81.30%
Delay between diagnosis and UDCA treatment (mo) (SD)	13.5 (38.8)
Complications	Acute cholangitis	15.10%
	Cholangiocarcinoma	2.80%
	Cirrhosis	20.80%
	Ascites	9.70%
	Gastrointestinal bleeding	5.70%
Non UDCA treatments	Corticosteroid	12.70%
	immunosuppressors	7%
	Liver transplantation	17.30%
Death	8.50%

PSC-IBD: Inflammatory bowel disease associated with primary sclerosing cholangitis; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic retrograde cholangiopancreatography; MRCP: Magnetic resonance cholangiopancreatography.